AstraZeneca PLC (CH:ZEG)
:ZEG
Want to see CH:ZEG full AI Analyst Report?
ZEG Stock Chart & Stats
CHF121.57
CHF0.00(0.00%)
At close: 4:00 PM EST
CHF121.57
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF121.57 - CHF121.57
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
CHF242.77B
Enterprise ValueCHF340.67B
Total Cash (Recent Filing)CHF5.74B
Total Debt (Recent Filing)CHF29.62B
Price to Earnings (P/E)28.1
BetaN/A
Next Earnings
Apr 29, 2026EPS Estimate
1.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.66
Shares Outstanding1,550,980,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)5.91
Price to Sales (P/S)4.90
P/FCF Ratio33.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF174.17Price Target Upside43.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)0.11
Revenue Forecast (FY)CHF669.64M
Bulls Say, Bears Say
Bulls Say
Broadened Patient EligibilityEvidence of efficacy across different eosinophil levels and in both current and former smokers could expand the eligible COPD population beyond type two-high patients, increasing potential market size.
Clinical Trial ResultsPositive Phase III results for tozorakimab showed clinically meaningful reductions in moderate-to-severe COPD exacerbations versus placebo, de-risking a potential multi-blockbuster commercial opportunity.
Diversified Late-stage PipelineA broad late-stage pipeline spanning oncology, cardiovascular, renal and rare disease programs, supported by strong prescription growth, creates multiple catalyst paths that could drive a favorable rerating if readouts remain positive.
Bears Say
Clinical And Execution RiskSeveral pivotal readouts carry outcome uncertainty and prior late-stage failures in the same drug class suggest execution and clinical risk that could generate negative readthroughs for related programs.
Competitive BenchmarkAn established competitor has already delivered exacerbation reductions and lung function improvement, creating a high clinical benchmark that may limit uptake if the new drug does not clearly outperform.
Pricing And Reimbursement PressureMandatory price reductions and value-based pricing arrangements for some medicines are likely to weigh on profitability and compress operating margins.
AstraZeneca News
ZEG FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest stock price was CHF121.57 and its highest was CHF121.57 in the past 12 months.
What is AstraZeneca PLC’s market cap?
AstraZeneca PLC’s market cap is CHF242.77B.
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Apr 29, 2026 which is in 11 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Feb 10, 2026. The company reported CHF1.657 earnings per share for the quarter, beating the consensus estimate of CHF1.634 by CHF0.023.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC does not currently pay dividends.
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is 1.97.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,980,800 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of CHF1.657 in its last earnings report, beating expectations of CHF1.634. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in CH:ZEG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF174.17 (43.26% Upside)
CHF174.17 (43.26% Upside)
Blogger Sentiment
Bullish
CH:ZEG Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.70%
12-Months-Change
Fundamentals
Return on Equity
23.00%
Trailing 12-Months
Asset Growth
2.10%
Trailing 12-Months
Company Description
AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
ZEG Stock 12 Month Forecast
Average Price Target
CHF174.17
▲(43.26% Upside)
Technical Analysis
ConvaTec
―
GlaxoSmithKline
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---